What pharma news happened in February 2023?

60 regulatory actions across global regulators, 0 Phase 3 trial completions, and 2 patent expiries — all sourced from primary regulatory + USPTO + ClinicalTrials.gov.

How fresh is this archive?

Each month's archive solidifies as it passes — the current month updates every 30 minutes; past months are stable historical archives.

February 2023 — Pharma News Archive

Every regulatory action (60), Phase 3 readout (0), and patent expiry (2) tracked in February 2023. Sourced from Drugs@FDA, EMA EPAR, ClinicalTrials.gov, USPTO Orange Book.

60 regulatory actions 0 Phase 3 readouts 2 patent expiries

Regulatory actions (60)

2023-02-28 — Tylenol · FDA · approved · US · Shanghai Zhongshan Hospital · Other
2023-02-28 — FEC-D · FDA · approved · US · Ottawa Hospital Research Institute · Other
2023-02-28 — Skyclarys · FDA · approved · US · Biogen Us · Other
2023-02-28 — Acetaminophen and Ibuprofen · FDA · approved · US · University of Manitoba · Pain Management, Fever Reduction
2023-02-28 — Taxotere · FDA · approved · US · Sanofi · Oncology
2023-02-28 — Zovirax · FDA · approved · US · Ligand Pharms · Immunology
2023-02-28 — Ganirelix - Delayed Puberty Ganirelix Visit · FDA · approved · US · University of Utah
2023-02-28 — Skyclarys · FDA · approved · US · Biogen Us · Other
2023-02-27 — SUN-101 via eFlow nebulizer · FDA · approved · US · Sunovion Respiratory Development Inc.
2023-02-27 — Glycopyrrolate · FDA · approved · US · Yonsei University · Metabolic
2023-02-27 — Eliquis · FDA · approved · US · Bristol-Myers Squibb · Cardiovascular
2023-02-27 — MEXILETINE HYDROCHLORIDE · FDA · approved · US
2023-02-27 — IOPAMIDOL · FDA · approved · US
2023-02-24 — Olmesartan medoxomil and hydrochlorothiazide · FDA · approved · US · Takeda
2023-02-24 — Zyprexa · FDA · approved · US · Eli Lilly · Neuroscience
2023-02-23 — SUN-101 via eFlow nebulizer · FDA · approved · US · Sunovion Respiratory Development Inc.
2023-02-23 — Glycopyrrolate · FDA · approved · US · Yonsei University · Metabolic
2023-02-23 — Ketorolac at high dose · FDA · approved · US · Tianjin Medical University General Hospital
2023-02-23 — Ketorolac at high dose · FDA · approved · US · Tianjin Medical University General Hospital
2023-02-20 — Imjudo · EMA · approved · EU · AstraZeneca · Oncology
2023-02-20 — Recombinant Human Adenovirus Type 5 Injection · EMA · withdrawn · EU · Sun Yat-sen University
2023-02-17 — Syfovre™ · FDA · approved · US · Hoffmann-La Roche · Ophthalmology
2023-02-17 — Zonalon · FDA · approved · US · Immunology
2023-02-17 — DOXEPIN HYDROCHLORIDE · FDA · approved · US
2023-02-17 — SPARSENTAN · FDA · approved · US
2023-02-15 — Magnesium Sulfate · FDA · approved · US · Pfizer
2023-02-15 — Tecfidera · EMA · withdrawn · EU · EMD Serono Research & Development Institute, Inc. · Immunology
2023-02-15 — Lymphostat B · FDA · approved · US · Human Genome Sciences Inc. · Oncology
2023-02-14 — Oseltamivir Phosphate For Oral Suspension · FDA · approved · US · The Affiliated Hospital of Qingdao University · Infectious Disease
2023-02-14 — Biaxin · FDA · approved · US · Generic (originally Abbott/AbbVie) · Infectious Disease
2023-02-13 — levonorgestrel and ethinyl estradiol · FDA · approved · US · Agile Therapeutics
2023-02-13 — Iressa · FDA · approved · US · Pfizer Inc. · Oncology
2023-02-10 — CABAZITAXEL · FDA · approved · US
2023-02-09 — Protonix · FDA · approved · US · Baxter
2023-02-09 — Vimpat · FDA · approved · US · UCB · Neuroscience
2023-02-09 — Rozerem · FDA · approved · US · Takeda · Metabolic
2023-02-09 — Quetiapine and Topiramate · FDA · approved · US · University of Cincinnati · Psychiatry / Neurology
2023-02-08 — Revlimid · FDA · approved · US · Bristol-Myers Squibb · Oncology
2023-02-07 — Glycopyrrolate · FDA · approved · US · Yonsei University · Metabolic
2023-02-07 — SUN-101 via eFlow nebulizer · FDA · approved · US · Sunovion Respiratory Development Inc.
2023-02-06 — Vimpat · FDA · approved · US · UCB · Neuroscience
2023-02-03 — Rexulti · FDA · approved · US · Otsuka · Neuroscience
2023-02-03 — OPC-34712 · FDA · approved · US · Otsuka Pharmaceutical Development & Commercialization, Inc. · Psychiatry/Neurology
2023-02-02 — SUCCINYLCHOLINE CHLORIDE · FDA · approved · US
2023-02-02 — Regadenoson · FDA · approved · US · Pfizer Inc. · Cardiovascular
2023-02-02 — Azole · FDA · approved · US · Erasmus Medical Center · Other
2023-02-02 — Succinylcholine Chloride · FDA · approved · US · Novartis · Neuroscience
2023-02-02 — VORICONAZOLE · FDA · approved · US
2023-02-02 — Pharmacologic Stress Agent · FDA · approved · US · Cedars-Sinai Medical Center
2023-02-01 — Jesduvroq · MOH · likely_approved · IL · GSK · Hematology
2023-02-01 — TOBRAMYCIN SULFATE · FDA · approved · US
2023-02-01 — Jesduvroq · FDA · approved · US · GSK · Hematology
2023-02-01 — Jesduvroq · FDA · approved · US · GSK · Hematology
2023-02-01 — Jesduvroq · MFDS · likely_approved · KR · GSK · Hematology
2023-02-01 — Jesduvroq · MOH · likely_approved · AE · GSK · Hematology
2023-02-01 — Vantobra · FDA · approved · US · Pfizer · Metabolic
2023-02-01 — Jesduvroq · SFDA · likely_approved · SA · GSK · Hematology
2023-02-01 — Vantobra · FDA · approved · US · Pfizer · Metabolic
2023-02-01 — Lipitor · FDA · approved · US · Pfizer · Metabolic
2023-02-01 — Jesduvroq · HSA · likely_approved · SG · GSK · Hematology

Phase 3 trial readouts (0)

No Phase 3 readouts tracked in this month.

Patent expiries (2)

2023-02-28 — Norgesic · 6926907 · US · Endo
2023-02-28 — Norgesic · 8206741 · US · Endo

Subscribe to ongoing alerts

This page is a permanent monthly archive. For ongoing alerts as new events happen:

February 2023 — Pharma News Archive

Regulatory actions (60)

Phase 3 trial readouts (0)

Patent expiries (2)

Subscribe to ongoing alerts

See also